Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2011

View Archived Issues

Eisai's Halaven injection approved in Singapore for metastatic breast cancer

Cardiac imaging using [123I]-mIBG can predict development of permanent atrial fibrillation

Dextran-coated iron oxide nanoparticles detect cholera enterotoxin with high sensitivity

Homocysteine level in serum is a biomarker for extent of vitiligo

Aptamer-targeted nanoparticle-encapsulated cisplatin prodrug shows promise in vivo

New inverse agonist of RAR-related orphan receptor-alpha SR-3335 improves glucose homeostasis

BioAlliance Pharma reports preliminary data from survey in patients with herpes labialis

PolyMedix begins phase II trial of PMX-60056 for reversal of heparin action in surgical setting

Teva Pharma reports phase III data on Qnaze in perennial allergic rhinitis

Novel urotensin UT receptor antagonists claimed by sanofi-aventis

CeNeRx presents first-in-human results on CXB-909

Cytokinetics and Amgen divulge design of phase IIb trial of intravenous omecamtiv mecarbil

Cephalon and Alba Therapeutics enter option agreement for larazotide acetate

GeoVax opens second site for ongoing HIV vaccine trial

First patient treated in CMV-ACE/ASPECT trial of preemptive cell therapy for CMV infection

Amicus Therapeutics begins phase II trial of Amigal plus ERT in Fabry's disease

European orphan drug status recommended for QLT-091001 in LCA and RP

Evotec enters definitive agreement to acquire Kinaxo Biotechnologies

Anacor and Medicis to collaborate on development of acne treatments

Futura Medical and Ansell enter commercialization agreement for PET-500

Eisai and Bial launch antiepileptic Zebinix in Spain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...